CX Institutional Buys 15,797 Shares of Pfizer Inc. $PFE

Key Points

• CX Institutional increased its holdings in Pfizer Inc. by 50.6%, owning a total of 47,032 shares worth approximately $1,140,000 by the end of the reporting period.
• Pfizer's quarterly earnings exceeded expectations with an EPS of $0.78, surpassing the consensus estimate of $0.58, alongside a reported revenue of $14.65 billion.
• Analyst ratings for Pfizer show a mixed outlook, with two "Strong Buy" ratings, four "Buy" ratings, eleven "Hold" ratings, and one "Sell" rating, reflecting varied market sentiment.

CX Institutional grew its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 50.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 47,032 shares of the biopharmaceutical company's stock after acquiring an additional 15,797 shares during the quarter. CX Institutional's holdings in Pfizer were worth $1,140,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Gould Capital LLC grew its holdings in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. acquired a new stake in shares of Pfizer in the first quarter valued at approximately $27,000. Bayforest Capital Ltd acquired a new stake in shares of Pfizer in the first quarter valued at approximately $28,000. North Capital Inc. acquired a new stake in shares of Pfizer in the first quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $30,000. 68.36% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Wall Street Zen raised Pfizer from a "hold" rating to a "buy" rating in a report on Saturday. Berenberg Bank decreased their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. Bank of America upped their price objective on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Finally, Morgan Stanley upped their price objective on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $28.12.

Pfizer Trading Down 0.5%

Shares of PFE opened at $24.03 on Monday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The business's fifty day moving average is $24.63 and its 200-day moving average is $24.20. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The firm has a market cap of $136.62 billion, a price-to-earnings ratio of 12.78, a PEG ratio of 0.78 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter last year, the company posted $0.60 EPS. The company's revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were given a dividend of $0.43 per share. The ex-dividend date was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.2%. Pfizer's payout ratio is currently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.